Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Jean Louis Selam"'
Autor:
Elisabetta Torlone, Reena Thomas, Philip Home, David Kerr, Geremia B. Bolli, Jean Louis Selam, Agnès Sola-Gazagnes, Ester Vitacolonna
Publikováno v:
Diabetes Care
OBJECTIVE Insulin pump therapy (continuous subcutaneous insulin infusion [CSII]) and multiple daily injections (MDIs) with insulin glargine as basal insulin and mealtime insulin lispro have not been prospectively compared in people naïve to either r
Autor:
Jean Louis Selam, Luigi F. Meneghini
Publikováno v:
Advances in Therapy. 26:194-207
The aim of this study was to compare a simplified patient-driven algorithm (303 Algorithm) to physician-driven adjustments in a subset of 193 patients with type 2 diabetes from the PREDICTIVE 303 study who were using basal-bolus insulin therapy.PREDI
Publikováno v:
Current Medical Research and Opinion. 24:11-20
PREDICTIVE 303 was a 26-week, prospective, randomized, open-label, multi-center study in patients with type 2 diabetes that investigated whether patient-driven adjustments of insulin detemir doses using the 303 Algorithm achieved similar glycemic con
Autor:
P. Urios, Jacques Peyroux, M. Sternberg, Jocelyne M'bemba, Jean-Louis Selam, Anne-Marie Borsos, Gérard Slama
Publikováno v:
Clinical biochemistry. 49(3)
Objective Advanced glycation end products (AGEs) of collagens appear to contribute to microvascular complications in diabetes. Do high concentrations of AGEs in skin collagen predict accelerated progression of these complications after 6 years and in
Autor:
Jean Louis Selam
Publikováno v:
Diabetes Research and Clinical Practice. 74:S123-S126
The use of CSII is progressively growing throughout the world, however a number of factors interfere with its diffusion and produce wide disparity between different countries. In USA around 20–25% of the population of Type 1 diabetics is treated wi
Autor:
Jean Louis Selam
Publikováno v:
Expert Opinion on Pharmacotherapy. 4:1373-1377
A non-invasive alternative to insulin injections would represent a major improvement for Type 1 and 2 insulin-treated patients. The lung is the only route which allows bio-availability of insulin, approaching 10% without absorption enhancers. However
Publikováno v:
Diabetes Care. 20:59-63
OBJECTIVE To examine the long-term benefits and risks of treatment of IDDM with an implantable programmable insulin pump. RESEARCH DESIGN AND METHODS Seventy-six patients with IDDM were studied at nine clinical centers. After 3–4 months of intensiv
Autor:
Brigitte Mace, Marie-Lou Ramaniche, Jean-Louis Selam, F. Bruzzo, Gérard Slama, M. J. Haardt, Catherine Dorange, Jean-Pierre Bethoux
Publikováno v:
Diabetes Care. 17:847-851
OBJECTIVE To investigate if intraperitoneal (IP) insulin infusion via programmable implantable pumps is a potential alternative to subcutaneous (SC) insulin via multiple injections. RESEARCH DESIGN AND METHODS We compared the cost-benefits of the two
Autor:
Jean-Louis Selam
The first manufactured insulin pump was introduced in the 1970s and the first insulin pens in 1985; since then, many improvements have been made to both devices. The advantages of pens over syringes have been confirmed in numerous studies and include
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62fb47d66cbab27fbbb08c55da877af9
https://europepmc.org/articles/PMC2901025/
https://europepmc.org/articles/PMC2901025/
Publikováno v:
Diabetes, obesitymetabolism. 9(6)
The Predictable Results and Experience in Diabetes through Intensification and Control to Target: An International Variability Evaluation 303 (PREDICTIVE 303) Study (n = 5604) evaluated the effectiveness of insulin detemir, a long-acting basal insuli